Authors
MI Gomez-Randulfe Rodriguez, C Escriu, S Mohammed, R Shah, JD Benitez Fuentes, S Cox, F Monaca, E Bria, S Silva Diaz, MR García Campelo, B Crook, T Talbot, R Leporati, K Balachandran, T Newsom-Davis, S Hughes, L Cove-Smith, P Taylor, F Blackhall, R Califano
Publication date
2024/3/1
Journal
ESMO Open
Volume
9
Publisher
Elsevier
Description
Background
Extensive Stage Small cell Lung Cancer (ES-SCLC) is an aggressive disease with poor outcomes. Although most patients (pts) initially respond to first-line (1L) treatment, eventually all will relapse. Second-line (2L) therapeutic options have limited efficacy. For pts with platinum-free interval (PFI)≥ 90 days, rechallenge with carboplatin-etoposide (CE) is a standard option. A phase 3, randomized trial comparing rechallenge CE vs topotecan in pts with PFI≥ 90 days, demonstrated longer progression-free survival (PFS) in the rechallenge group (4.7 m vs 2.7 m; HR= 0.57; p=. 0041) but similar (7.5 v 7.4 m) overall survival (OS). However, this study pre-dates the use of 1 st line chemo-immunotherapy (CT-IO) therefore the efficacy of platinum rechallenge after CT-IO is still unclear. Real-world data could offer valuable insights for this strategy.
Methods
We retrospectively reviewed pts with ES-SCLC who …
Scholar articles
MIGR Rodriguez, C Escriu, S Mohammed, R Shah… - ESMO Open, 2024